ConvaTec Group

ConvaTec Group is a holding company. Through its subsidiaries, Co. is a global medical products and technologies group. Co. has four franchises: Advanced Wound Care, which provides wound dressings, devices and skin care products used for the management of acute and chronic wounds; Ostomy Care, which focuses on devices, accessories and services for individuals who have a stoma; Continence and Critical Care, which provides products for people with urinary continence issues; and Infusion Devices, which develops and manufactures disposable infusion sets for the suppliers of insulin pumps for diabetes treatment and similar pumps used in continuous infusion treatments for other conditions.
  • TickerCTEC
  • ISINGB00BD3VFW73
  • ExchangeLondon Stock Exchange
  • SectorHealth Care Equipment & Services
  • CountryUnited Kingdom

Analysts

CONVATEC GROUP PLC. sees an upgrade to Slightly Positive due to a better fundamental star rating

The general evaluation of CONVATEC GROUP PLC. (GB), a company active in the Pharmaceuticals industry, has been upgraded by the independent financial analyst theScreener with the addition of a star. Its fundamental valuation now shows 4 out of 4 possible stars while its market behaviour can be considered as moderately risky. theScreener believes that the additional star(s) merits the upgrade of its general evaluation to Slightly Positive. As of the analysis date July 9, 2019, the closing price was GBp 146.65 and its potential was estimated at GBp 177.69.

Debbie Wang

Morningstar | ConvaTec's First-Quarter Revenue Results Held No Surprises; No Change to Our FVE

Narrow-moat ConvaTec posted first-quarter revenue results that were consistent with our measured expectations, and we’re holding steady on our fair value estimate. Quarterly organic revenue growth was down 2% year over year, reflecting weakness in advanced wound care and ostomy. In the past, we’ve described ConvaTec as a dumpster fire, and we now think it resembles more of a smoldering fire. Interim management has laid out a series of tactical plans to establish more strategic marketing, including the use of specialist sales reps and more clinical data to support its Aquacel wound care franchi...

Debbie Wang

ConvaTec's First-Quarter Revenue Results Held No Surprises; No Change to Our FVE

Narrow-moat ConvaTec posted first-quarter revenue results that were consistent with our measured expectations, and we’re holding steady on our fair value estimate. Quarterly organic revenue growth was down 2% year over year, reflecting weakness in advanced wound care and ostomy. In the past, we’ve described ConvaTec as a dumpster fire, and we now think it resembles more of a smoldering fire. Interim management has laid out a series of tactical plans to establish more strategic marketing, includi...

Expert Corporate Governance Service (ECGS)

ConvaTec Group - AGM 09 May 2019

Item 2: Approve the Remuneration Report  The structure of remuneration is considered unsatisfactory, though remuneration is weighted toward the long term. The quantum for the year was moderate.  Based on current disclosure, the loss of office payments appear acceptable. We recommend shareholders vote in favor.

1 director bought

A director at ConvaTec Group bought 55,500 shares at 137p and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board me...

Debbie Wang

Morningstar | ConvaTec's First-Quarter Revenue Results Held No Surprises; No Change to Our FVE

Narrow-moat ConvaTec posted first-quarter revenue results that were consistent with our measured expectations, and we’re holding steady on our fair value estimate. Quarterly organic revenue growth was down 2% year over year, reflecting weakness in advanced wound care and ostomy. In the past, we’ve described ConvaTec as a dumpster fire, and we now think it resembles more of a smoldering fire. Interim management has laid out a series of tactical plans to establish more strategic marketing, including the use of specialist sales reps and more clinical data to support its Aquacel wound care franchi...

Debbie Wang

ConvaTec's First-Quarter Revenue Results Held No Surprises; No Change to Our FVE

Narrow-moat ConvaTec posted first-quarter revenue results that were consistent with our measured expectations, and we’re holding steady on our fair value estimate. Quarterly organic revenue growth was down 2% year over year, reflecting weakness in advanced wound care and ostomy. In the past, we’ve described ConvaTec as a dumpster fire, and we now think it resembles more of a smoldering fire. Interim management has laid out a series of tactical plans to establish more strategic marketing, includi...

Debbie Wang

Morningstar | Narrow-Moat ConvaTec Tripped Up by Poor Execution

Since its initial public offering two years ago, ConvaTec has followed a familiar playbook to press its advantage in advanced wound care and enhance its ostomy business. By and large, we like ConvaTec’s businesses that focus on chronic care, which translates into an ongoing stream of revenue. However, the company has lagged significantly behind its key competitor, Coloplast. From our perspective, there is plenty of opportunity for ConvaTec to remedy the situation, but its ability to execute hinges greatly on new management.We like the firm's strategy of innovation and patient retention, but fo...

Debbie Wang

Narrow-Moat ConvaTec Tripped Up by Poor Execution

With ConvaTec plagued by operational difficulties and missteps over the last 18 months, we think it’s fair to say it currently looks more like a dumpster fire than anything else. We’re putting the company under review as we examine its challenges with the geographical relocation of key manufacturing facilities, aftermath of supply constraints, integration of recent acquisitions of distributors, and its ability to weather the tougher competitive conditions we’ve seen develop in the advanced wound...

Debbie Wang

Morningstar | ConvaTec Under Review as We Re-Evaluate Its Operational Challenges

With ConvaTec plagued by operational difficulties and missteps over the last 18 months, we think it’s fair to say it currently looks more like a dumpster fire than anything else. We’re putting the company under review as we examine its challenges with the geographical relocation of key manufacturing facilities, aftermath of supply constraints, integration of recent acquisitions of distributors, and its ability to weather the tougher competitive conditions we’ve seen develop in the advanced wound-care market. With former CEO Paul Moraviec moving on and an interim CEO in place, we think turning ...

1 director bought

A director at ConvaTec Group bought 55,500 shares at 137p and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board me...

CONVATEC GROUP PLC. sees an upgrade to Slightly Positive due to a better fundamental star rating

The general evaluation of CONVATEC GROUP PLC. (GB), a company active in the Pharmaceuticals industry, has been upgraded by the independent financial analyst theScreener with the addition of a star. Its fundamental valuation now shows 4 out of 4 possible stars while its market behaviour can be considered as moderately risky. theScreener believes that the additional star(s) merits the upgrade of its general evaluation to Slightly Positive. As of the analysis date July 9, 2019, the closing price was GBp 146.65 and its potential was estimated at GBp 177.69.

GlobalData Department

ConvaTec Group Plc (CTEC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Summary ConvaTec Group Plc (ConvaTec) is a medical products and technologies company that specializes in advanced wound care, ostomy care, continence and critical care, and infusion devices. Its major products include wound dressings, skin care products, disposable infusion sets, urological catheters, devices and accessories for people with ostomy, urinary continence issues related to spinal cord injuries, multiple sclerosis and spina bifida and other disorders. ConvaTec offers its products to hospitals, homecare agencies, pharmacies, insulin pump manufacturers and retail distributors caterin...

Expert Corporate Governance Service (ECGS)

ConvaTec Group - AGM 09 May 2019

Item 2: Approve the Remuneration Report  The structure of remuneration is considered unsatisfactory, though remuneration is weighted toward the long term. The quantum for the year was moderate.  Based on current disclosure, the loss of office payments appear acceptable. We recommend shareholders vote in favor.

Matthieu DRIOL

Analyse court terme - CONVATEC GROUP PLC : La tendance est baissière.

La tendance est baissière. Les prix baissent à nouveau, mais le mouvement est devenu hésitant. Le prochain support est à 189,08 p. La tendance baissière serait remise en cause au-dessus de 237,60 p.

Valérie GASTALDY

Analyse moyen terme - CONVATEC GROUP PLC : La tendance est haussière.

La tendance est haussière. La baisse récente gagne en vigueur. Le prochain support est à 179,14 p. La tendance serait remise en cause par la rupture de 179,14 p.

Matthieu DRIOL

Short term view - CONVATEC GROUP PLC : The trend is bearish.

The trend is bearish. Prices are falling again, but the movement has become hesitant. The next support is at 189.08 p. The bearish trend would be challenged above 237.60 p.

Valérie GASTALDY

Medium term view - CONVATEC GROUP PLC : The trend is bullish.

The trend is bullish. The recent fall is getting more vigorous. The next support is at 179.14 p. A break below 179.14 p would challenge the trend.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch